Edition:
Deutschland

Catabasis Pharmaceuticals Inc (CATB.OQ)

CATB.OQ on NASDAQ Stock Exchange Global Market

1.59USD
27 Nov 2020
Change (% chg)

$0.09 (+6.00%)
Prev Close
$1.50
Open
$1.51
Day's High
$1.62
Day's Low
$1.51
Volume
166,512
Avg. Vol
171,850
52-wk High
$8.59
52-wk Low
$1.25

About

Catabasis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapeutics. The Company’s lead product candidate is edasalonexent, an oral small molecule that inhibits nuclear factor kappa-light-chain-enhancer of activated B cells, in... (more)

Buy/Sell

Sell Hold Buy
3.00 Mean rating from 2 analysts

Overall

Beta: 2.08
Market Cap(Mil.): $31.93
Shares Outstanding(Mil.): 20.08
Dividend: --
Yield (%): --

BRIEF-Catabasis Names Ben Harshbarger Senior Vice President, General Counsel

* CATABASIS PHARMACEUTICALS NAMES BEN HARSHBARGER SENIOR VICE PRESIDENT, GENERAL COUNSEL Source text for Eikon: Further company coverage:

Märkte

  • U.S.
  • Europa
  • Asien
  • Branchen

Branchenüberblick

Energie +0.39%
Rohstoffe +0.14%
Industrie +0.31%
Konjunktur abhängige Waren & Dienstleistungen -0.01%
Konjunktur unabhängige Waren & Dienstleistungen -0.24%
Finanzindustrie +1.27%
Pharma +0.82%
Technologie +0.00%